Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2

1 Oct 2022

Abstract excerpt

Gene-based therapeutic strategies to lower ataxin-2 levels are emerging for the neurodegenerative diseases amyotrophic lateral sclerosis (ALS) and spinocerebellar ataxia type 2 (SCA2). Additional strategies to lower levels of ataxin-2 could be beneficial. Here, we perform a genome-wide arrayed small interfering RNA (siRNA) screen in human cells and identify RTN4R, the gene encoding the RTN4/NoGo-Receptor, as a...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Amyotrophic Lateral Sclerosis Research
Share to Genetic Neurodegenerative Diseases
Share to Ubiquitin and proteasome pathways

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36288715
DOI: 10.1016/j.celrep.2022.111505

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2PMID 36288715Read ↗

Targeting RTN4/NoGo-Receptor reduces levels of ALS protein ataxin-2Semantic proximity Read ↗

Small molecule v-ATPase inhibitor Etidronate lowers levels of ALS protein ataxin-2Semantic proximity Read ↗

Genome-wide CRISPR screen reveals v-ATPase as a drug target to lower levels of ALS protein ataxin-2Semantic proximity Read ↗

AAV-based delivery of RNAi targeting ataxin-2 improves survival and pathology in TDP-43 miceSemantic proximity Read ↗

EPHA4 is a disease modifier of amyotrophic lateral sclerosis in animal models and in humans.Semantic proximity Read ↗

AAV-based delivery of RNAi targeting Ataxin-2 improves survival, strength, and pathology in mouse models of rapidly and slowly progressive sporadic ALSSemantic proximity Read ↗

Treatment with an antibody directed against Nogo-A delays disease progression in the SOD1G93A mouse model of Amyotrophic lateral sclerosisSemantic proximity Read ↗

Rescue of amyotrophic lateral sclerosis phenotype in a mouse model by intravenous AAV9‐ADAR2 delivery to motor neuronsSemantic proximity Read ↗

Therapeutic reduction of ataxin-2 extends lifespan and reduces pathology in TDP-43 miceSemantic proximity Read ↗

Ataxin-2 modulates the levels of Grb2 and SRC but not ras signaling.Semantic proximity Read ↗

MiR-182-5p regulates Nogo-A expression and promotes neurite outgrowth of hippocampal neurons <i>in vitro</i>Semantic proximity Read ↗

New alternative splicing variants of the ATXN2 transcriptSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.